Colon cancer stem cells are believed to originate from a rare population of putative CD133+ intestinal stem cells. Recent publications suggest that a small subset of colon cancer cells expresses CD133, and that only these CD133+ cancer cells are capable of tumor initiation. However, the precise contribution of CD133+ tumor-initiating cells in mediating colon cancer metastasis remains unknown. Therefore, to temporally and spatially track the expression of CD133 in adult mice and during tumorigenesis, we generated a knockin lacZ reporter mouse (CD133lacZ/+), in which the expression of lacZ is driven by the endogenous CD133 promoters. Using this model and immunostaining, we discovered that CD133 expression in colon is not restricted to stem cells; on the contrary, CD133 is ubiquitously expressed on differentiated colonic epithelium in both adult mice and humans. Using Il10–/–CD133lacZ mice, in which chronic inflammation in colon leads to adenocarcinomas, we demonstrated that CD133 is expressed on a full gamut of colonic tumor cells, which express epithelial cell adhesion molecule (EpCAM). Similarly, CD133 is widely expressed by human primary colon cancer epithelial cells, whereas the CD133– population is composed mostly of stromal and inflammatory cells. Conversely, CD133 expression does not identify the entire population of epithelial and tumor-initiating cells in human metastatic colon cancer. Indeed, both CD133+ and CD133– metastatic tumor subpopulations formed colonospheres in in vitro cultures and were capable of long-term tumorigenesis in a NOD/SCID serial xenotransplantation model. Moreover, metastatic CD133– cells form more aggressive tumors and express typical phenotypic markers of cancer-initiating cells, including CD44 (CD44+CD24–), whereas the CD133+ fraction is composed of CD44lowCD24+ cells. Collectively, our data suggest that CD133 expression is not restricted to intestinal stem or cancer-initiating cells, and during the metastatic transition, CD133+ tumor cells might give rise to the more aggressive CD133– subset, which is also capable of tumor initiation in NOD/SCID mice.
Sergey V. Shmelkov, Jason M. Butler, Andrea T. Hooper, Adilia Hormigo, Jared Kushner, Till Milde, Ryan St. Clair, Muhamed Baljevic, Ian White, David K. Jin, Amy Chadburn, Andrew J. Murphy, David M. Valenzuela, Nicholas W. Gale, Gavin Thurston, George D. Yancopoulos, Michael D’Angelica, Nancy Kemeny, David Lyden, Shahin Rafii
Title and authors | Publication | Year |
---|---|---|
CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin
S Friedman, M Lu, A Schultz, D Thomas, RY Lin |
PloS one | 2009 |
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment
G Bertolini, L Roz, P Perego, M Tortoreto, E Fontanella, L Gatti, G Pratesi, A Fabbri, F Andriani, S Tinelli, E Roz, R Caserini, SL Vullo, T Camerini, L Mariani, D Delia, E Calabrò, U Pastorino, G Sozzi |
Proceedings of the National Academy of Sciences | 2009 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Crosstalk of Notch with p53 and p63 in cancer growth control
GP Dotto |
Nature Reviews Cancer | 2009 |
Loss of the Cholesterol-Binding Protein Prominin-1/CD133 Causes Disk Dysmorphogenesis and Photoreceptor Degeneration
S Zacchigna, H Oh, M Wilsch-Brauninger, E Missol-Kolka, J Jaszai, S Jansen, N Tanimoto, F Tonagel, M Seeliger, WB Huttner, D Corbeil, M Dewerchin, S Vinckier, L Moons, P Carmeliet |
The Journal of neuroscience : the official journal of the Society for Neuroscience | 2009 |
Colon cancer stem cells
L Ricci-Vitiani, E Fabrizi, E Palio, RD Maria |
Journal of Molecular Medicine | 2009 |
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells
KS Chan, I Espinosa, M Chao, D Wong, L Ailles, M Diehn, H Gill, J Presti, HY Chang, M de Rijn, L Shortliffe, IL Weissman |
Proceedings of the National Academy of Sciences | 2009 |
Melanoma-initiating cells: a compass needed
Y Refaeli, A Bhoumik, DR Roop, ZA Ronai |
EMBO reports | 2009 |
High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells
PE Burger, R Gupta, X Xiong, CS Ontiveros, SN Salm, D Moscatelli, EL Wilson |
Stem Cells | 2009 |
Identification of gastric cancer stem cells using the cell surface marker CD44
S Takaishi, T Okumura, S Tu, SS Wang, W Shibata, R Vigneshwaran, SA Gordon, Y Shimada, TC Wang |
Stem Cells | 2009 |
The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer
SK Basak, MS Veena, S Oh, G Huang, E Srivatsan, M Huang, S Sharma, RK Batra |
PloS one | 2009 |
Characterisation of normal and cancer stem cells: One experimental paradigm for two kinds of stem cells
JF Mayol, C Loeuillet, F Hérodin, D Wion |
BioEssays | 2009 |
Stem cells in gastroenterology and hepatology
M Quante, TC Wang |
Nature reviews. Gastroenterology & hepatology | 2009 |
Isolation of tumour stem-like cells from benign tumours
Q Xu, X Yuan, P Tunici, G Liu, X Fan, M Xu, J Hu, JY Hwang, DL Farkas, KL Black, JS Yu |
British Journal of Cancer | 2009 |
New Therapeutics Targeting Colon Cancer Stem Cells
A Thenappan, Y Li, K Shetty, L Johnson, EP Reddy, L Mishra |
Current Colorectal Cancer Reports | 2009 |
Characterization of CD133+ parenchymal cells in the liver: histology and culture
S Yoshikawa, Y Zen, T Fujii, Y Sato, T Ohta, Y Aoyagi, Y Nakanuma |
World journal of gastroenterology : WJG | 2009 |
Glioblastoma formation from cell population depleted of Prominin1-expressing cells
K Nishide, Y Nakatani, H Kiyonari, T Kondo |
PloS one | 2009 |
Expression of stem cell markers in the human fetal kidney
S Metsuyanim, O Harari-Steinberg, E Buzhor, D Omer, N Pode-Shakked, H Ben-Hur, R Halperin, D Schneider, B Dekel |
PloS one | 2009 |
Tumor biology and cancer therapy - an evolving relationship
T Seufferlein, J Ahn, D Krndija, U Lother, G Adler, G Wichert |
Cell communication and signaling : CCS | 2009 |
Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness
LB Weiswald, S Richon, P Validire, M Briffod, R Lai-Kuen, FP Cordelières, F Bertrand, D Dargere, G Massonnet, E Marangoni, B Gayet, M Pocard, I Bieche, MF Poupon, D Bellet, V Dangles-Marie |
British Journal of Cancer | 2009 |
Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB
CY Li, BX Li, Y Liang, RQ Peng, Y Ding, DZ Xu, X Zhang, ZZ Pan, DS Wan, YX Zeng, XF Zhu, XS Zhang |
Journal of Translational Medicine | 2009 |
Number crunching in the cancer stem cell market
MR Alison, S Islam, SM Lim |
Breast Cancer Research | 2009 |
Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis
EH Huang, MJ Hynes, T Zhang, C Ginestier, G Dontu, H Appelman, JZ Fields, MS Wicha, BM Boman |
Cancer research | 2009 |
Expression of gastrin precursors by CD133-positive colorectal cancer cells is crucial for tumour growth
A Ferrand, MS Sandrin, A Shulkes, GS Baldwin |
Biochimica et Biophysica Acta | 2009 |
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling
L Lin, R Amin, GI Gallicano, E Glasgow, W Jogunoori, JM Jessup, M Zasloff, JL Marshall, K Shetty, L Johnson, L Mishra, AR He |
Oncogene | 2009 |
Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion
F Varnat, A Duquet, M Malerba, M Zbinden, C Mas, P Gervaz, AR Altaba |
EMBO Molecular Medicine | 2009 |
Cancer stem cells in multiple myeloma
N Ghosh, W Matsui |
Cancer Letters | 2009 |
SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma
Son MJ, Woolard K, Nam DH, Lee J, Fine HA |
Cell Stem Cell | 2009 |
Characterization of human embryonic stem cells with features of neoplastic progression.
Werbowetski-Ogilvie TE, Bossé M, Stewart M, Schnerch A, Ramos-Mejia V, Rouleau A, Wynder T, Smith MJ, Dingwall S, Carter T, Williams C, Harris C, Dolling J, Wynder C, Boreham D, Bhatia M |
Nature Biotechnology | 2009 |
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications.
Ischenko I, Seeliger H, Kleespies A, Angele MK, Eichhorn ME, Jauch KW, Bruns CJ |
Langenbeck's Archives of Surgery | 2009 |
Endothelial progenitor cell dysfunction in rheumatic disease.
Westerweel PE, Verhaar MC |
Nature reviews. Rheumatology | 2009 |
Stem cells and solid cancers.
McDonald SA, Graham TA, Schier S, Wright NA, Alison MR |
Virchows Archiv : an international journal of pathology | 2009 |
Both CD133+ and CD133− subpopulations of A549 and H446 cells contain cancer‐initiating cells
Meng X, Li M, Wang X, Wang Y, Ma D |
Cancer Science | 2009 |